ArriVent BioPharma, Inc. AVBP

AVBP Company Overview

ArriVent BioPharma, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of differentiated medicines for cancers with high unmet medical need. The company operates within the oncology biopharmaceutical industry and concentrates primarily on precision therapies targeting solid tumors driven by defined genetic mutations or molecular pathways. Its lead development programs are centered on targeted cancer therapeutics, with a strategic emphasis on leveraging global licensing opportunities to advance assets for international markets, particularly the United States and other major oncology markets.

The company’s primary revenue and value drivers are tied to its clinical development pipeline, regulatory milestones, and potential future commercialization of oncology therapies. ArriVent has positioned itself as a development-focused oncology company that seeks to identify promising clinical assets from global biotechnology ecosystems and advance them through multinational clinical programs. The company was founded in 2021 by executives with prior experience in oncology drug development and public biotechnology companies. ArriVent completed its initial public offering on the Nasdaq Global Market under the ticker AVBP in 2024, expanding access to capital for clinical development and operational growth.